Systemic vasculitides are a heterogeneous group of diseases characterized by inflammation of vessels, which can result in their obstruction and/or aneurysm formation. The evidence of the inflammation of blood vessel walls in at least one occasion during the course is a shared defining feature of all categories of vasculitis. Their classification varies according to etiology, pathogenesis, type of vessel affected, type of inflammation, and favored organ distribution. Almost all primary vasculitides can target the heart; even if cardiac manifestations are rarely predominant, they can be life threatening and, therefore, require specific diagnostic and therapeutic strategies. Although cardiac involvement occurs in less than 10% of all patients affected by systemic vasculitides, certain entities, such as eosinophilic granulomatosis with polyangiitis (EGPA) and Takayasu’s arteritis (TAK) can cause heart complications in up to 60% of patients. After briefly reviewing the definitions, classification, and pathogenic mechanisms of vasculitides, we describe the cardiac manifestations that can occur in each vasculitis and their corresponding therapies.
Cardiac Involvement in Systemic Vasculitis / Sebastiani, Marco; Manfredi, Andreina Teresa; Ferri, Clodoveo. - 14:(2017), pp. 335-376. [10.1016/B978-0-12-803997-7.00014-4]
Cardiac Involvement in Systemic Vasculitis
SEBASTIANI, Marco;MANFREDI, Andreina Teresa;FERRI, Clodoveo
2017
Abstract
Systemic vasculitides are a heterogeneous group of diseases characterized by inflammation of vessels, which can result in their obstruction and/or aneurysm formation. The evidence of the inflammation of blood vessel walls in at least one occasion during the course is a shared defining feature of all categories of vasculitis. Their classification varies according to etiology, pathogenesis, type of vessel affected, type of inflammation, and favored organ distribution. Almost all primary vasculitides can target the heart; even if cardiac manifestations are rarely predominant, they can be life threatening and, therefore, require specific diagnostic and therapeutic strategies. Although cardiac involvement occurs in less than 10% of all patients affected by systemic vasculitides, certain entities, such as eosinophilic granulomatosis with polyangiitis (EGPA) and Takayasu’s arteritis (TAK) can cause heart complications in up to 60% of patients. After briefly reviewing the definitions, classification, and pathogenic mechanisms of vasculitides, we describe the cardiac manifestations that can occur in each vasculitis and their corresponding therapies.File | Dimensione | Formato | |
---|---|---|---|
Heart in vasculitis.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
3.96 MB
Formato
Adobe PDF
|
3.96 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris